« Previous AbstractBacterial periplasmic permeases belong to a family of transport proteins operating from Escherichia coli to human: Traffic ATPases    Next AbstractIn vitro Antibacterial Activity and Phytochemical Analysis of Nicotiana tabacum L. Extracted in Different Organic Solvents »

BMC Complement Med Ther

Title:		Chemical composition of essential oils of eight Tunisian Eucalyptus species and their antibacterial activity against strains responsible for otitis
Author(s):		Ameur E; Sarra M; Yosra D; Mariem K; Nabil A; Lynen F; Larbi KM;
Address:		"Chemical, Pharmacological and Gallenic Development Laboratory, University of Monastir, Faculty of Pharmacy, Avenue Avicennne, 5000, Monastir, Tunisia. aelaissi@yahoo.fr. Chemical, Pharmacological and Gallenic Development Laboratory, University of Monastir, Faculty of Pharmacy, Avenue Avicennne, 5000, Monastir, Tunisia. University of Carthage, The National Research Institute of Rural Engineering, Water and Forestry, INRGREF, Laboratory of Management and Valorization of Forest Resources, BP 10, 2080, Ariana, Tunisia. Laboratory of Transmissible Diseases and Biological Active Substances LR99ES27, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia. High Institute of Biotechnology of Sidi Thabet, University of Manouba, Manouba, Tunisia. Separation Science Group, Department of Organic and Macromolecular Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281-S4 Bis, B-9000, Ghent, Belgium"
Journal Title:		BMC Complement Med Ther
Year:		2021
Volume:		20210812
Issue:		1
Page Number:		209 -
DOI:		10.1186/s12906-021-03379-y
ISSN/ISBN:		2662-7671 (Electronic) 2662-7671 (Linking)
Abstract:		"BACKGROUND: The chemical composition and biological activity of Eucalyptus essential oils have been studied extensively (EOs). A few of them were tested for antibacterial effectiveness against otitis strains. The chemical composition and antibacterial activity of the EOs of eight Tunisian Eucalyptus species were assessed in the present study. METHODS: Hydrodistillation was used to extract EOs from the dried leaves of eight Eucalyptus species: Eucalyptus accedens, Eucalyptus punctata, Eucalyptus robusta, Eucalyptus bosistoana, Eucalyptus cladocalyx, Eucalyptus lesouefii, Eucalyptus melliodora and Eucalyptus wandoo. They are assessed by GC/MS and GC/FID and evaluated for antibacterial activity using agar diffusion and broth microdilution techniques against three bacterial isolates (Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae) and three reference bacteria strains (Pseudomonas aeruginosa, ATTC 9027; Staphylococcus aureus, ATCC 6538; and Escherichia coli, ATCC 8739). Furthermore, the selected twenty-one major compounds and all values of the inhibition zone diameters were subjected to further statistical analysis using PCA and HCA. RESULTS: The EO yields of the studied Eucalyptus species range from 1.4 +/- 0.4% to 5.2 +/- 0.3%. Among all the species studied, E. lesouefii had the greatest mean percentage of EOs. The identification of 128 components by GC (RI) and GC/MS allowed for 93.6% - 97.7% of the total oil to be identified. 1,8-cineole was the most abundant component found, followed by alpha-pinene, p-cymene, and globulol. The chemical components of the eight EOs, extracted from the leaves of Eucalyptus species, were clustered into seven groups using PCA and HCA analyses, with each group forming a chemotype. The PCA and HCA analyses of antibacterial activity, on the other hand, identified five groups. CONCLUSION: The oils of E. melliodora, E. bosistoana, and E. robusta show promise as antibiotic alternatives in the treatment of otitis media"
Keywords:		"Anti-Bacterial Agents/*pharmacology Eucalyptus/*chemistry Humans Microbial Sensitivity Tests Oils, Volatile/*pharmacology Otitis/*drug therapy Plant Oils/*pharmacology Antibacterial activity Chemical composition Essential oils Eucalyptus Hierarchical Clus;"
Notes:		"MedlineAmeur, Elaissi Sarra, Moumni Yosra, Derbali Mariem, Khouja Nabil, Abid Lynen, Frederic Larbi, Khouja Mohamed eng England 2021/08/14 BMC Complement Med Ther. 2021 Aug 12; 21(1):209. doi: 10.1186/s12906-021-03379-y"